For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
1
views
117
references
 Top references
cited by
1
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      2,113
      similar
       All similar
      • Record: found
      • Abstract: not found
      • Article: not found

      Emerging pharmacotherapies for the treatment of pulmonary arterial hypertension

      Author(s): 1 , 1
      Publication date (Electronic):
      Journal: Expert Opinion on Investigational Drugs

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Most cited references117

          • Record: found
          • Abstract: found
          • Article: not found

          Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

          Bernard Zinman, Christoph Wanner, John M. Lachin … (2015)
          The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known.
          Article 0 comments Cited 2357 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

            Milton Packer, Stefan D. Anker, Javed Butler … (2020)
            Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart failure, including those with a markedly reduced ejection fraction.
            Article 0 comments Cited 1460 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).

              Nazzareno Galiè, Marc Humbert, Jean-Luc Vachiéry … (2015)
              Article 0 comments Cited 1276 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Title: Expert Opinion on Investigational Drugs
                Abbreviated Title: Expert Opinion on Investigational Drugs
                ISSN (Print): 1354-3784
                ISSN (Electronic): 1744-7658
                Publication date Created: November 02 2023
                Publication date (Electronic): October 30 2023
                Publication date (Print): November 02 2023
                Volume: 32
                Issue: 11
                Pages: 1025-1042
                Affiliations
                [1 ]Division of Pulmonary, Sleep and Critical Care Medicine, Rhode Island Hospital and the Alpert Medical School of Brown University, Providence, RI, USA
                Article
                DOI: 10.1080/13543784.2023.2274439
                SO-VID: 32a09126-6df0-46eb-92b2-c6cdbc53b9e5
                Copyright © © 2023
                History

                Data availability:

                Comments

                Comment on this article